ARMP: Gunggung utang perusahaan Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals focuses on creating innovative treatments against resistant bacteria using phage therapy. This price chart demonstrates the asset's dynamics, with debt obligations currently at 0.00. The business occupies a specific medical niche, minimizing scientific risks. Furthermore, developments in the US and the humanitarian profile of its activities make the company resilient to external political shocks and sanctions.

This indicator tracks the total volume of external liabilities, reflecting the business's degree of dependence on borrowed capital. An increase in this metric indicates the use of leverage, while a decrease signals enhanced financial autonomy. The trend in total debt allows for an assessment of bankruptcy risk. This is critical for Armata Pharmaceuticals (ARMP), as the absence of revenue leaves the company vulnerable. The current debt level determines the margin of safety until the commercialization of bacteriophages.